Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2020-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Severe peanut allergy is different from other allergic reactions because it can lead to fatal reactions and is an invisible disability. There is no cure today. The purpose of this study is to treat children and adolescents with severe peanut allergy with oral immunotherapy with peanuts under the protection of anti-IgE (immunoglobulin E) antibodies (omalizumab), and thereby inducing tolerance to peanuts. The treatment will be monitored by basophil cell stimulation (CD-sens).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Omalizumab in the Treatment of Peanut Allergy

NCT00949078

Food Allergy Peanut Allergy

COMPLETED PHASE2

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

NCT01781637

Peanut Allergy Food Allergy

COMPLETED PHASE1/PHASE2

A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

NCT00382148

Peanut Hypersensitivity

COMPLETED PHASE2

A Safety and Efficacy Study of Xolair in Peanut Allergy

NCT00086606

Allergy

TERMINATED PHASE2

Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)

NCT04037176

Food Allergy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Oral immunotherapy (OIT), where the food protein is consumed in increasing amounts, have been studied with good results, but allergic reactions has been a major problem. Anti-IgE antibodies (omalizumab) block allergy antibodies so that the allergic reaction is absent. A new test in which basophil cells stimulated with allergen in vitro, CD-sens, showing cell sensitivity, correlates well to peanut challenges.

Twenty children/adolescents, 12 to 22 years, with severe peanut allergy will be treated with omalizumab and the effect evaluated with CD-sens. If the CD-sens is negative a peanut challenge will be performed. If the challenge is negative the OIT will start: 1, 2, 4, 8 g peanuts/day in two-week intervals followed by a maintenance dose of 10 g peanuts/day while continuing treatment with omalizumab. If the CD-sens is still negative the withdrawal of omalizumab will start by halving the dose in several steps.

The study is independent of pharmaceutical companies. Omalizumab is dosed according to body mass and the amount of total IgE antibodies and therefore every individual has an individual study duration. In average the duration of the study is estimated to 52 weeks +/-40/20 weeks. Inclusion in the study is expected to last for the 2 coming years.

A treatment without serious side effects for those with severe food allergies would give a great benefit with reduced anxiety and fear, but also major health economic benefits in the form of fewer hospitalizations, sick leave, and to a greater extent completed school and education.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peanut Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Omalizumab

Omalizumab is given to protect the study object from severe allergic reactions while they are going through oral immunotherapy with peanuts. There wïll be only one arm. The study objects are their own controls by also having allergy to airborne allergens. The dose is calculated by the study objects body mass and number of total IgE antibodies.

Group Type EXPERIMENTAL

Omalizumab

Intervention Type DRUG

Omalizumab is the treatment during oral immunotherapy with peanuts as protection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omalizumab

Omalizumab is the treatment during oral immunotherapy with peanuts as protection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* IgE to peanut, Ara h 1, Ara h 2 and Ara h 3
* IgE to an airborne allergen i.e. cat, dog, horse, birch, grass etc.
* Clinical allergic reactions to peanut the last 5 years
* Positive conjunctival challenge to the selected airborne allergen
* Positive CD-sens to peanut and the selected airborne allergen
* IgE according to the recommendations of the manufacturer
* Written consent

Exclusion Criteria

* No severe diseases like renal failure, hart disease, immunodeficiency, diabetes or other severe chronic diseases
* Pregnancy
* No previous hypersensitivity reactions to sucrose, histidine, polysorbat 20 or omalizumab

Minimum Eligible Age

12 Years

Maximum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No